FDA-cleared profile

BoneView

Gleamer · X-ray/Radiography · FDA-cleared (510(k))

Concurrent-reading software that highlights suspected fractures on labeled adult radiographs for physician review.

Clinical role
Concurrent fracture-detection support during radiograph interpretation.
Images and patients
X-ray/Radiography · Ankle, foot, knee, tibia/fibula, femur, wrist, hand, elbow, forearm, humerus, shoulder, clavicle, pelvis, hip, ribs, thoracic spine, and lumbosacral spine
Key limitation
The cleared scope covers labeled adult radiograph views only. The output is an aid, not a replacement for full image review, clinical examination, or judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?It analyzes radiographs and highlights areas suspicious for fractures as a concurrent reading aid during physician interpretation.
  • Which images is it intended for?It accepts DICOM radiographs of labeled adult extremity, pelvic, rib, and spine regions, including the ankle, wrist, shoulder, hip, ribs, and thoracic or lumbosacral spine.
  • Who uses it?Radiologists, physicians, and trained radiology or orthopedic professionals use it in radiology and orthopedic imaging workflows.
  • What does the software produce?It returns result DICOM images and summary information with annotations or highlighted areas; the original images are not altered.
  • What is its most important limitation?The labeled use is limited to supported adult radiograph views. Results aid, but do not replace, full image review, clinical examination, or physician judgment.

Clinical takeaway. BoneView adds concurrent fracture highlights within its labeled adult radiograph scope; clinicians still perform the complete image review and clinical assessment.

Evidence takeaway. The FDA submission reports standalone fracture-detection results from 8,918 adult radiographs at two operating points. Those results are limited to the stated endpoint, population, operating point, and BoneView version; they are not reader-aided or site-performance claims.

Additional limitations
  • The FDA package describes DICOM integration and on-premises or cloud options, but does not establish current local hosting, security, availability, configuration, pricing, or reimbursement.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
BoneView is a concurrent reading aid that analyzes radiographs and highlights areas suspicious for fractures in adults during physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Concurrent fracture-detection support during radiograph interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM radiographs of the labeled adult extremity, pelvic, rib, and spine regions.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Result DICOM images and summary information with annotations or highlighted areas; original images are not altered.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiology and orthopedic imaging workflows in hospitals, clinics, and imaging sites.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists, physicians, and trained radiology or orthopedic professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling limits the supported adult radiograph views and requires physician interpretation. Results are an aid and do not replace full image review, clinical examination, or judgment.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports standalone testing on 8,918 radiographs: examination-level sensitivity 0.928 [0.919 - 0.936] and specificity 0.811 [0.8 - 0.821] at the high-sensitivity operating point, and sensitivity 0.841 [0.829 - 0.853] and specificity 0.932 [0.925 - 0.939] at the high-specificity operating point. In a fully-crossed MRMC retrospective reader study (24 readers, 480 cases), reader sensitivity improved from 0.648 (95% bootstrap CI: 0.640-0.656) to 0.752 (0.745-0.759) and specificity from 0.906 (0.898-0.913) to 0.956 (0.951-0.960) with BoneView. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Gleamer performed a standalone performance testing on a dataset of 8,918 radiographs" … "of BoneView at the examination-level at the high-sensitivity operating point and high-specificity operating point on the merged datasets High-sensitivity operating point High-specificity operating point Standalone Specificity – 95% Sensitivity – 95% Specificity – 95% Sensitivity". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports standalone testing on 8,918 radiographs: examination-level sensitivity 0.928 [0.919 - 0.936] and specificity 0.811 [0.8 - 0.821] at the high-sensitivity operating point, and sensitivity 0.841 [0.829 - 0.853] and specificity 0.932 [0.925 - 0.939] at the high-specificity operating point. In a fully-crossed MRMC retrospective reader study (24 readers, 480 cases), reader sensitivity improved from 0.648 (95% bootstrap CI: 0.640-0.656) to 0.752 (0.745-0.759) and specificity from 0.906 (0.898-0.913) to 0.956 (0.951-0.960) with BoneView. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Gleamer performed a standalone performance testing on a dataset of 8,918 radiographs" … "of BoneView at the examination-level at the high-sensitivity operating point and high-specificity operating point on the merged datasets High-sensitivity operating point High-specificity operating point Standalone Specificity – 95% Sensitivity – 95% Specificity – 95% Sensitivity". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Value withdrawn pending re-verification
  • Corrected record
  • Exact FDA submission
  • Checked 2026-09-14

Previous value withdrawn: The legacy value combines multiple unlabeled numbers and does not identify an endpoint, operating point, population, or tested version. Use the scoped exact-submission evidence metrics instead.

Reported specificity
Value withdrawn pending re-verification
  • Corrected record
  • Exact FDA submission
  • Checked 2026-09-14

Previous value withdrawn: The legacy value combines multiple unlabeled numbers and does not identify an endpoint, operating point, population, or tested version. Use the scoped exact-submission evidence metrics instead.

Standalone sensitivity at high-sensitivity operating point

92.8 percent

  • EndpointFracture detection sensitivity
  • PopulationGlobal adult radiograph standalone dataset
  • Tested versionBoneView

Standalone specificity at high-sensitivity operating point

81.1 percent

  • EndpointFracture detection specificity
  • PopulationGlobal adult radiograph standalone dataset
  • Tested versionBoneView

Standalone sensitivity at high-specificity operating point

84.1 percent

  • EndpointFracture detection sensitivity
  • PopulationGlobal adult radiograph standalone dataset
  • Tested versionBoneView

Standalone specificity at high-specificity operating point

93.2 percent

  • EndpointFracture detection specificity
  • PopulationGlobal adult radiograph standalone dataset
  • Tested versionBoneView

K212365 FDA evidence package for BoneView

  • DesignFDA 510(k) standalone performance evaluation.
  • PopulationStandalone performance data from 8,918 adult radiographs across the labeled body regions.
  • Scopeexact submission
  • Tested versionBoneView
  • Samplen=8918
  • IndependenceSponsor or vendor study

K212365

FDA-reported global operating-point results for the exact BoneView submission.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K212365 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM radiographs of the labeled adult extremity, pelvic, rib, and spine regions.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView

  2. Routing

    Source context, not route validation: The FDA package describes DICOM source and destination through PACS or an X-ray system, with an intermediate DICOM node, gateway, or API for processing and result return.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView

  3. AI processing

    Source context, not route validation: The FDA package describes on-premises or cloud deployment options; current hosting, security, availability, and local configuration remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView

  4. Returned objects

    Source context, not route validation: Result DICOM images and summary information with annotations or highlighted areas; original images are not altered.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView

  5. Viewer/worklist/report

    Unresolved route: Result DICOM images and summary information with annotations or highlighted areas; original images are not altered.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes on-premises or cloud deployment options; current hosting, security, availability, and local configuration remain unknown.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes DICOM source and destination through PACS or an X-ray system, with an intermediate DICOM node, gateway, or API for processing and result return.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by radiologists, physicians, and trained radiology or orthopedic professionals. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K212365.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K212365.

exact submission · checked 2026-09-04

Deployment boundary

The FDA package describes on-premises or cloud deployment options; current hosting, security, availability, and local configuration remain unknown.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes DICOM source and destination through PACS or an X-ray system, with an intermediate DICOM node, gateway, or API for processing and result return.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K212365.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K212365
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Ankle, foot, knee, tibia/fibula, femur, wrist, hand, elbow, forearm, humerus, shoulder, clavicle, pelvis, hip, ribs, thoracic spine, and lumbosacral spine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-03-01
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. Several records name BoneView, but none identifies the tested build tied to K212365; NCT04532580 says FDA submission but omits the submission number and software version, and other records are pediatric, family-level, or unrelated. The current discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K212365: BoneView

    U.S. Food and Drug Administration - Published 2022-03-01 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. BoneView model card (K212365)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K212365 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253192

DeepXray Spina

Alpha Intelligence Manifolds, Inc.

Authorized purpose: Opportunistic review of frontal lumbar-spine or KUB radiographs in adults aged 50 years and older to flag possible low bone mineral density at L1-L4 for clinician follow-up; a negative result does not rule out low BMD.

Modality
X-ray/Radiography
Anatomy
Spine/Bone Health
Decision
2026-06-10
FDA-cleared K260378

Rayvolve

AZmed

Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.

Modality
X-ray/Radiography
Anatomy
Musculoskeletal and chest/ribs radiographs across specified views
Decision
2026-05-12
FDA-cleared K252953

Velmeni for Dentists (V4D) Endo-Perio

Velmeni, Inc.

Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Decision
2026-05-11
FDA-cleared K251934

qXR-Detect

Qure.Ai Technologies

Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.

Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Decision
2026-01-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history